MiniMed Group (NASDAQ:MMED) Sets New 1-Year Low – Should You Sell?

MiniMed Group Inc (NASDAQ:MMED)’s share price reached a new 52-week low on Thursday . The company traded as low as $13.52 and last traded at $14.03, with a volume of 44988 shares traded. The stock had previously closed at $14.48.

Key MiniMed Group News

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Barclays started coverage with an “overweight” rating and a $26 price target (~80% upside vs. current levels), a clear bullish signal that may drive buying interest. Barclays Overweight, $26 PT
• Positive Sentiment: Bank of America initiated coverage with a Buy rating and a $27 price target, highlighting expectations for pipeline-driven growth after MiniMed’s spin-off — another strong endorsement from a major broker. Bank of America Buy, $27 PT
• Positive Sentiment: Goldman Sachs initiated coverage — high-profile analyst coverage often boosts visibility and can attract institutional flows. Coverage Initiated at The Goldman Sachs Group
• Positive Sentiment: Morgan Stanley began coverage, adding another large sell-side name now tracking MMED which may increase research-driven demand. Morgan Stanley Begins Coverage
• Neutral Sentiment: Evercore initiated coverage; initiation itself raises profile though no publicized rating/target was cited in the item. Coverage Initiated at Evercore
• Neutral Sentiment: Wells Fargo started coverage — added research coverage increases investor access but headline lacked a disclosed PT. Wells Fargo Initiates Coverage
• Neutral Sentiment: Piper Sandler initiated coverage; more broker coverage typically improves trading interest. Piper Sandler Initiates Coverage
• Neutral Sentiment: Deutsche Bank began coverage — another institutional research addition that may increase visibility. Deutsche Bank Begins Coverage
• Neutral Sentiment: Citigroup, BTIG, Mizuho and William Blair also initiated coverage; collectively these add breadth to sell-side coverage but most reports did not publish immediate price targets in the summaries. Citigroup Coverage BTIG Coverage Mizuho Begins Coverage William Blair Coverage

Analyst Ratings Changes

A number of research firms have commented on MMED. The Goldman Sachs Group began coverage on MiniMed Group in a research note on Tuesday. They issued a “buy” rating and a $24.00 price target for the company. Wells Fargo & Company began coverage on shares of MiniMed Group in a report on Tuesday. They set an “overweight” rating and a $26.00 price objective on the stock. Bank of America initiated coverage on shares of MiniMed Group in a research report on Tuesday. They issued a “buy” rating and a $27.00 price objective for the company. Mizuho initiated coverage on shares of MiniMed Group in a research note on Tuesday. They set an “outperform” rating and a $21.00 price target on the stock. Finally, William Blair initiated coverage on shares of MiniMed Group in a report on Tuesday. They issued an “outperform” rating for the company. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, MiniMed Group presently has a consensus rating of “Moderate Buy” and an average target price of $22.45.

MiniMed Group Stock Down 2.3%

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.